Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.

Tadmor T, Benjamini O, Goldschmidt N, Kreiniz N, Bairey O, Harel R, Sarid N, Levi T, Wolach O, Herishanu Y.

Open source

DOI: 10.3324/haematol.2026.300749
Published: 2026-05-07
Container: Haematologica
Publisher: Not recorded
Open access: no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.300749,
  title = {Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.},
  author = {Tadmor T and  Benjamini O and  Goldschmidt N and  Kreiniz N and  Bairey O and  Harel R and  Sarid N and  Levi T and  Wolach O and  Herishanu Y.},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.300749},
  url = {https://doi.org/10.3324/haematol.2026.300749}
}

RIS

TY  - JOUR
TI  - Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.
AU  - Tadmor T
AU  -  Benjamini O
AU  -  Goldschmidt N
AU  -  Kreiniz N
AU  -  Bairey O
AU  -  Harel R
AU  -  Sarid N
AU  -  Levi T
AU  -  Wolach O
AU  -  Herishanu Y.
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.300749
UR  - https://doi.org/10.3324/haematol.2026.300749
ER  -

APA

T, T., O, B., N, G., N, K., O, B., R, H., N, S., T, L., O, W., & Y., H. (2026). Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.. Haematologica. https://doi.org/10.3324/haematol.2026.300749

Source records

europe-pmc · retrieved 2026-09-27T08:18:17.540Z
doaj · retrieved 2026-09-27T08:18:17.560Z